{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:43:31Z","timestamp":1794541411700,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00228-020-03047-z","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T20:03:49Z","timestamp":1605729829000},"page":"671-676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Influence of formulation and route of administration on ketamine\u2019s safety and tolerability: systematic review"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-2800","authenticated-orcid":false,"given":"Paul","family":"Glue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J.","family":"Medlicott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"issue":"4","key":"3047_CR1","doi-asserted-by":"publisher","first-page":"pyv124","DOI":"10.1093\/ijnp\/pyv124","volume":"19","author":"Y Xu","year":"2016","unstructured":"Xu Y, Hackett M, Carter G, Loo C, G\u00e1lvez V, Glozier N, Glue P, Lapidus K, McGirr A, Somogyi AA, Mitchell PB (2016) Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol 19(4):pyv124. https:\/\/doi.org\/10.1093\/ijnp\/pyv124","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"3047_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1903305","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim J, Farchione T, Potter A, Chen Q, Temple R (2019) Esketamine for treatment-resistant depression\u2014first FDA-approved antidepressant in a new class. N Engl J Med 381(1):1\u20134. https:\/\/doi.org\/10.1056\/NEJMp1903305","journal-title":"N Engl J Med"},{"key":"3047_CR3","unstructured":"https:\/\/www.statnews.com\/2020\/01\/06\/only-15-vets-treated-esketamine\/. Accessed 12\/7\/20"},{"key":"3047_CR4","unstructured":"https:\/\/www.nice.org.uk\/news\/article\/nasal-spray-medicine-for-treatment-resistant-depression-not-recommended-by-nice. Accessed 12\/7\/20"},{"issue":"1","key":"3047_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/acps.12572","volume":"134","author":"CK Loo","year":"2016","unstructured":"Loo CK, G\u00e1lvez V, O'Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J, Harper S, Somogyi AA, Lai R, Weickert CS, Glue P (2016) Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand 134(1):48\u201356. https:\/\/doi.org\/10.1111\/acps.12572","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"3047_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/0269881119874457","volume":"34","author":"P Glue","year":"2020","unstructured":"Glue P, Neehoff S, Sabadel A, Broughton L, Le Nedelec M, Shadli S, McNaughton N, Medlicott NJ (2020) Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol 34(3):267\u2013272. https:\/\/doi.org\/10.1177\/0269881119874457","journal-title":"J Psychopharmacol"},{"key":"3047_CR7","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211243lbl.pdf. Accessed 5\/11\/20"},{"key":"3047_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fphar.2018.00733","volume":"9","author":"EE Schenberg","year":"2018","unstructured":"Schenberg EE (2018) Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Front Pharmacol 9:733. https:\/\/doi.org\/10.3389\/fphar.2018.00733","journal-title":"Front Pharmacol"},{"issue":"1","key":"3047_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/ALN.0000000000000285","volume":"121","author":"RK Paul","year":"2014","unstructured":"Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, O\u2019Loughlin K, Torjman MC, Bernier M, Wainer IW (2014) (R, S)-Ketamine metabolites (R, S)-norketamine and (2S, 6S)-hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology 121(1):149\u2013159. https:\/\/doi.org\/10.1097\/ALN.0000000000000285","journal-title":"Anesthesiology"},{"issue":"7604","key":"3047_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KSS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate Jr CA, Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533(7604):481\u2013486. https:\/\/doi.org\/10.1038\/nature17998","journal-title":"Nature"},{"issue":"1","key":"3047_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1192\/bjp.2018.196","volume":"214","author":"Y Domany","year":"2019","unstructured":"Domany Y, Bleich-Cohen M, Tarrasch R, Meidan R, Litvak-Lazar O, Stoppleman N, Schreiber S, Bloch M, Hendler T, Sharon H (2019) Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry 214(1):20\u201326. https:\/\/doi.org\/10.1192\/bjp.2018.196","journal-title":"Br J Psychiatry"},{"issue":"2","key":"3047_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1192\/bjp.bp.115.165498","volume":"208","author":"RA Schoevers","year":"2016","unstructured":"Schoevers RA, Chaves TV, Balukova SM, Kortekaas R (2016) Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry 208(2):108\u2013113. https:\/\/doi.org\/10.1192\/bjp.bp.115.165498","journal-title":"Br J Psychiatry"},{"key":"3047_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/ptj\/89.9.873","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269. https:\/\/doi.org\/10.1093\/ptj\/89.9.873","journal-title":"Ann Intern Med"},{"issue":"1","key":"3047_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 11(1):125\u2013136. https:\/\/doi.org\/10.1023\/A:1024465317902","journal-title":"J Trauma Stress"},{"issue":"5","key":"3047_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/jps.2600710516","volume":"71","author":"JA Clements","year":"1982","unstructured":"Clements JA, Nimmo WS, Grant IS (1982) Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 71(5):539\u2013542. https:\/\/doi.org\/10.1002\/jps.2600710516","journal-title":"J Pharm Sci"},{"issue":"2","key":"3047_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/bja\/77.2.203","volume":"77","author":"JM Malinovsky","year":"1996","unstructured":"Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M (1996) Ketamine and norketamine plasma concentrations after iv, nasal and rectal administration in children. Br J Anaesth 77(2):203\u2013207","journal-title":"Br J Anaesth"},{"issue":"1","key":"3047_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/bdd.336","volume":"24","author":"Y Yanagihara","year":"2003","unstructured":"Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T (2003) Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 24(1):37\u201343. https:\/\/doi.org\/10.1002\/bdd.336","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"3047_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/00044011-200929050-00004","volume":"29","author":"C Chong","year":"2009","unstructured":"Chong C, Schug SA, Page-Sharp M, Jenkins B, Ilett KF (2009) Development of a sublingual\/oral formulation of ketamine for use in neuropathic pain. Clin Drug Invest 29(5):317\u2013324. https:\/\/doi.org\/10.2165\/00044011-200929050-00004","journal-title":"Clin Drug Invest"},{"key":"3047_CR19","unstructured":"Bitter C (2010) Pharmacokinetics and pharmacodynamics of nasally applied esketamine. PhD thesis. https:\/\/edoc.unibas.ch\/1310\/1\/20110314_1408_DissCB_e_version.pdf. Accessed 3\/4\/20"},{"issue":"12","key":"3047_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1460-9592.2004.01358.x","volume":"14","author":"F Weber","year":"2004","unstructured":"Weber F, Wulf H, Gruber M, Biallas R (2004) S-ketamine and s-norketamine plasma concentrations after nasal and iv administration in anesthetized children. Pediatr Anesth 14(12):983\u2013988","journal-title":"Pediatr Anesth"},{"issue":"5","key":"3047_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1742-7843.2012.00908.x","volume":"111","author":"MA Peltoniemi","year":"2012","unstructured":"Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Kurkinen KJ, Neuvonen PJ, Olkkola KT (2012) Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine. Basic Clin Pharmacol Toxicol 111(5):325\u2013332. https:\/\/doi.org\/10.1111\/j.1742-7843.2012.00908.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"3047_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-015-1826-y","volume":"71","author":"S Fanta","year":"2015","unstructured":"Fanta S, Kinnunen M, Backman JT, Kalso E (2015) Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol 71(4):441\u2013447. https:\/\/doi.org\/10.1007\/s00228-015-1826-y","journal-title":"Eur J Clin Pharmacol"},{"key":"3047_CR23","unstructured":"Manthei SA, Rey H, Fischer M, Mundszinger O, inventors; Develco Pharma Schweiz AG, assignee (2019) Oral dosage forms of ketamine. United States Patent US 10,335,379. Accessed 3\/4\/20"},{"key":"3047_CR24","unstructured":"Hasan M (2017) Pharmacokinetics and disposition of prolonged-release ketamine tablets for treatment of neuro-psychiatric diseases. Doctoral thesis. https:\/\/epub.ub.uni-greifswald.de\/frontdoor\/deliver\/index\/docId\/1997\/file\/diss_Hasan_Mahmoud.pdf. Accessed 3\/4\/20"},{"issue":"8","key":"3047_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/bja\/53.8.805","volume":"53","author":"IS Grant","year":"1981","unstructured":"Grant IS, Nimmo WS, Clements JA (1981) Pharmacokinetics and analgesic effects of im and oral ketamine. Br J Anaesth 53(8):805\u2013810","journal-title":"Br J Anaesth"},{"issue":"4","key":"3047_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/ALN.0000000000001798","volume":"127","author":"K Jonkman","year":"2017","unstructured":"Jonkman K, Duma A, Olofsen E, Henthorn T, van Velzen M, Mooren R, Siebers L, van den Beukel J, Aarts L, Niesters M, Dahan A (2017) Pharmacokinetics and bioavailability of inhaled esketamine in healthy volunteers. Anesthesiology 127(4):675\u2013683. https:\/\/doi.org\/10.1097\/ALN.0000000000001798","journal-title":"Anesthesiology"},{"issue":"4","key":"3047_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ejpain.2009.08.002","volume":"14","author":"V Huge","year":"2010","unstructured":"Huge V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, Azad SC (2010) Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain 14(4):387\u2013394. https:\/\/doi.org\/10.1016\/j.ejpain.2009.08.002","journal-title":"Eur J Pain"},{"issue":"2","key":"3047_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/pan.12268","volume":"24","author":"BN Nielsen","year":"2014","unstructured":"Nielsen BN, Friis SM, R\u00f8msing J, Schmiegelow K, Anderson BJ, Ferreiros N, Labocha S, Henneberg SW (2014) Intranasal sufentanil\/ketamine analgesia in children. Paediatr Anaesth 24(2):170\u2013180","journal-title":"Paediatr Anaesth"},{"issue":"6","key":"3047_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1460-9592.2011.03548.x","volume":"21","author":"KE Brunette","year":"2011","unstructured":"Brunette KE, Anderson BJ, Thomas J, Wiesner L, Herd DW, Schulein S (2011) Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. Paediatr Anaesth 21(6):653\u2013662. https:\/\/doi.org\/10.1111\/j.1460-9592.2011.03548.x","journal-title":"Paediatr Anaesth"},{"issue":"6","key":"3047_CR30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bcp.12264","volume":"77","author":"P Rolan","year":"2014","unstructured":"Rolan P, Lim S, Sunderland V, Liu Y, Molnar V (2014) The absolute bioavailability of racemic ketamine from a novel sublingual formulation. Br J Clin Pharmacol 77(6):1011\u20131016","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3047_CR31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/jcph.1573","volume":"60","author":"P Glue","year":"2020","unstructured":"Glue P, Medlicott NJ, Surman P, Lam F, Hung N, Hung CT (2020) Ascending-dose study of controlled-release ketamine tablets in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol 60(6):751\u2013757. https:\/\/doi.org\/10.1002\/jcph.1573","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3047_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2044.1983.tb10376.x","volume":"38","author":"J Idvall","year":"1983","unstructured":"Idvall J, Holasek J, P\u00e5l Stenberg V (1983) Rectal ketamine for induction of anaesthesia in children. Anaesthesia 38(1):60\u201364","journal-title":"Anaesthesia"},{"issue":"6","key":"3047_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/bja\/63.6.671","volume":"63","author":"JL Pedraz","year":"1989","unstructured":"Pedraz JL, Calvo MB, Lanao JM, Muriel C, Lamas JS, Dominguez-Gil A (1989) Pharmacokinetics of rectal ketamine in children. Br J Anaesth 63(6):671\u2013674","journal-title":"Br J Anaesth"},{"key":"3047_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jcrc.2016.05.016","volume":"35","author":"BL Erstad","year":"2016","unstructured":"Erstad BL, Patanwala AE (2016) Ketamine for analgosedation in critically ill patients. J Crit Care 35:145\u2013149. https:\/\/doi.org\/10.1016\/j.jcrc.2016.05.016","journal-title":"J Crit Care"},{"key":"3047_CR35","doi-asserted-by":"publisher","first-page":"204512532092247","DOI":"10.1177\/2045125320922474","volume":"10","author":"P Glue","year":"2020","unstructured":"Glue P, Medlicott NJ, Neehoff S, Surman P, Lam F, Hung N, Hung CT (2020) Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. Ther Adv Psychopharmacol 10:2045125320922474. https:\/\/doi.org\/10.1177\/2045125320922474","journal-title":"Ther Adv Psychopharmacol"},{"key":"3047_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00406-020-01110-5","volume":"20","author":"GC Leal","year":"2020","unstructured":"Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LN, Marback RF, Caliman-Fontes AT (2020) Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci 20:1\u20136. https:\/\/doi.org\/10.1007\/s00406-020-01110-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3047_CR37","doi-asserted-by":"publisher","first-page":"119291","DOI":"10.1016\/j.ijpharm.2020.119291","volume":"4","author":"FY Han","year":"2020","unstructured":"Han FY, Liu Y, Kumar V, Xu W, Yang G, Zhao CX, Woodruff TM, Whittaker AK, Smith MT (2020) Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation. Int J Pharm 4:119291. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119291","journal-title":"Int J Pharm"},{"key":"3047_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jconrel.2020.03.026","volume":"322","author":"AJ Courtenay","year":"2020","unstructured":"Courtenay AJ, McAlister E, McCrudden MT, Vora L, Steiner L, Levin G, Levy-Nissenbaum E, Shterman N, Kearney MC, McCarthy HO, Donnelly RF (2020) Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery. J Control Release 322:177\u2013186. https:\/\/doi.org\/10.1016\/j.jconrel.2020.03.026","journal-title":"J Control Release"},{"issue":"4","key":"3047_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18103\/mra.v6i4.1749","volume":"6","author":"R Kubota","year":"2018","unstructured":"Kubota R, Maruyama Y, Wada Y, Okamoto A, Tsukamoto A, Komiyama T (2018) The development of transdermal ketamine patch. Med Res Arch 6(4):1\u20139. https:\/\/doi.org\/10.18103\/mra.v6i4.1749","journal-title":"Med Res Arch"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03047-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-020-03047-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03047-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T13:04:15Z","timestamp":1617887055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-020-03047-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3047"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03047-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Drs Glue and Medlicott have a contract with Douglas Pharmaceuticals to develop novel ketamine formulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}